Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma

Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia
Surovatamig plus rituximab induces high complete response rates in previously untreated follicular lymphoma ( Prof Chan Cheah - Sir Charles Gairdner Hospital, Perth, Australia )
18 Jun 2026

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Dr Frederick Chen - Barts Health NHS Trust, London, UK
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )
18 Jun 2026

CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia

Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark
CLL TIM risk model predicts infection and treatment need in newly diagnosed chronic lymphocytic leukaemia ( Prof Carsten Niemann - Rigshospitalet, Copenhagen, Denmark )
18 Jun 2026

Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Prof Anthony Moorman - Newcastle University, Newcastle, UK
Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL ( Prof Anthony Moorman - Newcastle University, Newcastle, UK )
18 Jun 2026

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas

Prof Marek Trněný - Charles University, Prague, Czechia
Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas ( Prof Marek Trněný - Charles University, Prague, Czechia )
18 Jun 2026

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany
Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival ( Prof Martin Schrappe - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )
18 Jun 2026

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA
Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL ( Dr Andrew Kuykendall - Moffitt Cancer Center, Tampa, USA )
1 Jun 2026

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma ( Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2026

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA
Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment ( Dr Karen Mustian - Wilmot Cancer Institute, Rochester, USA )
31 May 2026

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas

Dr Georg Lenz - University Hospital Münster, Münster, Germany
Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas ( Dr Georg Lenz - University Hospital Münster, Münster, Germany )
30 May 2026